(0.06%) 5 183.97 points
(0.04%) 38 869 points
(-0.16%) 16 323 points
(0.08%) $78.54
(0.46%) $2.21
(-0.38%) $2 322.40
(-0.44%) $27.49
(2.37%) $987.80
(0.22%) $0.930
(0.89%) $10.92
(0.47%) $0.800
(-0.05%) $91.30
Quarter results tomorrow
(amc 2024-05-08)
Expected move: +/- 6.23%
-2.54% $ 4.26
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 2.67M |
Średni wolumen | 4.85M |
Kapitalizacja rynkowa | 290.22M |
EPS | $0 ( 2024-03-11 ) |
Następna data zysków | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -425.93 |
ATR14 | $0.0200 (0.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 0 | |
2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
INSIDER POWER |
---|
64.88 |
Last 98 transactions |
Buy: 4 891 928 | Sell: 1 103 909 |
Wolumen Korelacja
CytomX Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GURE | 0.925 |
EYEG | 0.922 |
DIBS | 0.919 |
SWVL | 0.918 |
EIGR | 0.917 |
JOAN | 0.917 |
AFIB | 0.916 |
LPSN | 0.913 |
QRTEA | 0.912 |
RUBY | 0.911 |
10 Najbardziej negatywne korelacje | |
---|---|
SGEN | -0.906 |
GETVV | -0.903 |
STAY | -0.894 |
PUCKU | -0.887 |
TVTY | -0.886 |
CCRC | -0.886 |
DSPG | -0.884 |
ALTR | -0.875 |
SNCR | -0.875 |
MTEK | -0.873 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CytomX Therapeutics Inc Korelacja - Waluta/Towar
CytomX Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $101.21M |
Zysk brutto: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
Przychody: | $101.21M |
Zysk brutto: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
Przychody: | $53.16M |
Zysk brutto: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
Przychody: | $69.57M |
Zysk brutto: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej